Antonio Giordano, MD, PhD

Antonio Giordano, MD, PhD is a breast medical oncologist at Dana-Farber Cancer Institute. During his PhD program in medical oncology and immunology, he studied the biology and clinical relevance of circulating tumor cells (CTC) and cancer-initiating stem cells in breast cancer. During the four years spent as faculty at MD Anderson, he consolidated his solid foundation in breast clinical oncology, transitional and basic science research, and has made tremendous contributions to the field of breast cancer biology. He received two prestigious grant awards, the 2012 AACR-Bristol-Myers Squibb Oncology fellowship in clinical cancer research and the 2012 ASCO Young Investigator Award, for a project on single-nucleus DNA sequencing to investigate CTC origin in breast cancer patients. In 2016 he joined the Division of Hematology/Oncology at MUSC in Charleston SC and received the K12 Paul Calabresi & Translational Oncology Training Program Award with a laboratory project on triple-negative breast cancer and Polo-like kinase 1. Dr. Giordano was awarded the METAVIVOR Early Career Investigator Award to support a phase 1 clinical trial with a Plk1 inhibitor in metastatic breast cancer patients with TP53 mutation. At Dana-Farber Cancer Institute he is a Clinical Investigator in the Breast Oncology Center and Center for Cancer Therapeutic Innovation. His main area of interest is HR+ metastatic breast cancer and cell cycle inhibition. He is the Principal Investigator on many clinical trials, including selective CDK4 and CDK2 inhibitors, KAT6A inhibitors, PIK3CA mutant selective inhibitors, and new antibody drug conjugates. Dr. Giordano believes that oncology is a diversified discipline and to be involved in research to beat cancer would be his prerogative as a translational oncologist.